Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson DiseaseGlobeNewsWire • 12/09/20
GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman SyndromeGlobeNewsWire • 12/05/20
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare DiseasesGlobeNewsWire • 11/09/20
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 11/02/20
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/28/20
GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman SyndromeGlobeNewsWire • 10/26/20
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular DystrophyGlobeNewsWire • 10/23/20
Ultragenyx to Host Conference Call for Third Quarter 2020 Financial Results and Corporate UpdateGlobeNewsWire • 10/21/20
Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources OfficerGlobeNewsWire • 09/01/20
Ultragenyx (RARE) Up 10.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 08/29/20
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/31/20
Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate UpdateGlobeNewsWire • 07/30/20
Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate UpdateGlobeNewsWire • 07/24/20
Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation DisordersGlobeNewsWire • 07/22/20